A COVID-19 protease inhibition assay has been developed to screen compounds for potential hits, which can then be evaluated in downstream models for potential antiviral therapies for COVID-19.
Proteases are found in almost every organism and contribute to cellular processes by catalyzing the proteolytic cleavage of specific target sequences. Viruses use proteases to process strings of viral precursor proteins into mature components of the viral machinery, such as structural proteins of the viral capsid, replicases, and other non-structural proteins. The central function of viral proteases makes them ideal targets in small molecule inhibitors screening.
Accelerate Your COVID-19 Therapeutic Development
Learn how to screen your antivirals with our new viral COVID-19 protease inhibition assay.
Our scientists have developed and validated a robust in vitro assay using a COVID-19 main protease expressed in E. coli cells. Proteolytic cleavage of a peptide substrate conjugated with a fluorophore (EDANS) and a quencher (DABCYL) causes robust and measurable fluorescence emission directly proportional to the protease activity. Compounds identified as hits through this screening process can then be evaluated in downstream models for potential antiviral therapies for COVID-19.